Question 1

A 24-year-old woman reports that her new therapist is "the best therapist I've ever had — nothing like the last one who was terrible." Three weeks later, after the therapist sets a boundary about after-hours calls, the patient says the therapist is "cold and doesn't care about me at all." Which defense mechanism is most prominently demonstrated?

Accepted Answer

This is a classic splitting vignette. The patient alternates between viewing the therapist as entirely good (idealization) and entirely bad (devaluation), with the shift triggered by a perceived rejection (boundary-setting). Splitting is a primitive defense mechanism central to BPD in which the patient cannot hold a nuanced view that integrates both positive and negative qualities of the same person. Projection involves attributing one's own unacceptable feelings to another. Displacement redirects emotions from their original target to a safer one. Reaction formation involves expressing the opposite of a threatening impulse.

Question 2

A 29-year-old patient presents with mood instability, impulsive spending, and interpersonal conflict. Her mood shifts occur within hours and are triggered by arguments with her partner. She denies decreased need for sleep, denies grandiosity, and describes chronic feelings of emptiness and fear that her partner will leave her. Which feature most reliably distinguishes this presentation from bipolar II disorder?

Accepted Answer

Duration and reactivity of mood episodes is the most reliable differentiator. BPD mood shifts are reactive to interpersonal triggers and last hours to occasionally a few days. Bipolar hypomanic episodes must last at least 4 days and often emerge without a clear interpersonal cause. Impulsive spending can occur in both conditions. Interpersonal conflict does not exclude bipolar disorder. Chronic emptiness supports BPD but does not exclude bipolar comorbidity — and importantly, both diagnoses can co-occur.

Question 3

A patient with known BPD presents to the emergency department with suicidal ideation following a breakup. She has presented with similar complaints 6 times in the past year. The most appropriate initial response is:

Accepted Answer

The diagnosis does not make suicidality less dangerous — it makes it more frequent. With an estimated 8-10% completed suicide rate in BPD, every presentation requires a thorough risk assessment. Habituation to a patient's repeated crises is both a clinical and medicolegal risk. Dismissive reassurance based on prior presentations is dangerous. Routine involuntary admission is not indicated for chronic suicidality in BPD and can be counterproductive. Benzodiazepines are high-risk in BPD due to paradoxical disinhibition and dependence potential.

Question 4

What is the first-line treatment for borderline personality disorder?

Accepted Answer

DBT is the evidence-based first-line treatment for BPD. It has the strongest evidence for reducing suicidal behavior, self-harm, and treatment dropout. There is no FDA-approved medication for BPD. Pharmacotherapy is adjunctive and symptom-targeted only. Benzodiazepines are specifically high-risk in BPD due to paradoxical disinhibition and dependence potential — this is a commonly tested board point.

Question 5

A BPD patient with anxiety and impulsivity asks for "something to take the edge off." She has a history of alcohol use disorder. Which medication class should be avoided?

Accepted Answer

Benzodiazepines are high-risk in BPD presentations due to paradoxical disinhibition and dependence potential, compounded by the high rate of substance use comorbidity and chronic suicidality. This patient's AUD history further increases the risk. SSRIs have modest evidence for impulsivity in BPD. SGAs may help with affective dysregulation and transient psychotic symptoms. Mood stabilizers may help with impulsivity and affective instability.

Borderline Personality Disorder

Red Flags & Key Clinical Considerations

Suicidality

Splitting in the Treatment Team

Countertransference

Benzodiazepine Risk

Diagnostic Disclosure

Related Medications

References & Further Reading